Pradeep Bekal, MD
Gastroenterology · Cincinnati, OHNPI 1730178633
Payments from drug & device makers
What this record shows
It is spread thinly across 35 manufacturers, the largest accounting for just 19.9%. 2025 is the largest year on record at $6,808, 8.1 times the $843 reported in 2019.
Across 506 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- AbbVie$2K
- Bausch Health US, LLC$2K
- Pentax Of America, Inc.$2K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$662
- plus $4K from 29 others
Across 262 payments — averaging $5338.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$371K
- Bristol Myers Squibb$362K
- Gilead$221K
- Takeda Pharmaceuticals U.S.A., Inc.$178K
- AbbVie$93K
- Ironwood Pharmaceuticals, Inc$56K
- plus $118K from 6 others
What the payments were for
- Consulting fees$6,40847%
- Food & beverage$7,36453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $2,737 |
| AbbVie | 226 | $2,352 |
| Bausch Health US, LLC | 2 | $1,710 |
| Pentax Of America, Inc. | 1 | $1,500 |
| AstraZeneca | 1 | $1,058 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $662 |
| Johnson & Johnson(2 entities) | 23 | $509 |
| Gilead | 28 | $426 |
| Regeneron Healthcare Solutions, Inc. | 19 | $335 |
| Bristol Myers Squibb | 16 | $269 |
| Madrigal Pharmaceuticals | 5 | $200 |
| Pfizer | 13 | $196 |
| Medtronic | 4 | $192 |
| Sanofi | 11 | $184 |
| Nestle Healthcare Nutrition Inc. | 9 | $149 |
| Ironwood Pharmaceuticals, Inc | 10 | $146 |
| Merck | 6 | $144 |
| QOL Medical, LLC | 7 | $136 |
| Boston Scientific | 1 | $123 |
| Ferring Pharmaceuticals Inc. | 8 | $117 |
| Lilly USA, LLC | 4 | $92 |
| Amgen | 5 | $79 |
| Ipsen Biopharmaceuticals, Inc | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 1 | $67 |
| Celltrion USA Inc. | 3 | $55 |
| Ardelyx, Inc. | 3 | $52 |
| Novo Nordisk | 3 | $45 |
| Apollo Endosurgery US Inc | 3 | $44 |
| Braintree Laboratories, Inc. | 2 | $29 |
| Cook Medical LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $16 |
| UCB, Inc. | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $12 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,772 in reported general payments places this provider in the 80th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 35 | $99,574 |
| Mesalamine | 52 | $33,546 |
| LinzessLinaclotide | 31 | $26,462 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 52 | $7,260 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 97 | $5,842 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 35 | $5,648 |
| Mesalamine ErMesalamine | 12 | $1,214 |
| Omeprazole | 157 | $1,197 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 90 | $1,177 |
| Ondansetron Hcl | 12 | $857 |
| Budesonide DrBudesonide | 15 | $731 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 32 | $580 |
| Dicyclomine Hcl | 16 | $552 |
| Pantoprazole Sodium | 36 | $430 |
| Famotidine | 16 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,352 | $126,03666 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $2,737 | $7,26052 claims |
| Braintree Laboratories, Inc.Sutab | $29 | $5,64835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cincinnati
- Anita AfzaliCincinnati$798K
- Kara de FeliceCincinnati$427K
- Allan PeckCincinnati$391K
- Ravi RavinuthalaCincinnati$302K
- Robert IsfortCincinnati$162K
- Luis LaraCincinnati$146K
- Vidhya KunnathurCincinnati$96K
- Moamen GabrCincinnati$70K
- Lisa LestinaCincinnati$59K
- Naim AlkhouriWestlake$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.